Citadel Advisors
SHPH icon

Citadel Advisors’s Shuttle Pharmaceuticals SHPH Stock Holding History

Citadel Advisors’s Portfolio SHPH Stock Details SHPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$79.2K Buy
+24,354
New +$159K ﹤0.01% 12850
2025
Q2 		– Sell
-380
Closed -$36.9K – 14822
2025
Q1 		$36.9K Buy
+380
New +$61.7K ﹤0.01% 12614

Other funds holding SHPH

HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
KFA
Kelleher Financial Advisors New York $705M AUM 16.14% 1-Year Est. Return

Citadel Advisors's SHPH Position: Q2 2026 in Review

Citadel Advisors opened a new position in Shuttle Pharmaceuticals (SHPH) in Q2 2026: 24,354 shares worth $79.2K. The stake represents ﹤0.01% of the portfolio and ranks #12850 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in SHPH as recently as Q1 2025.

Citadel Advisors first reported a position in SHPH in Q1 2025 and has held it in 2 quarters since. 5 funds tracked by Wall St. Rank hold SHPH as of Q2 2026.

  • Citadel Advisors held 24,354 shares of Shuttle Pharmaceuticals worth $79.2K as of Q2 2026.
  • Shuttle Pharmaceuticals was a new Citadel Advisors position in Q2 2026.
  • Shuttle Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #12850 holding.
  • Citadel Advisors first reported a position in Shuttle Pharmaceuticals in Q1 2025 and has held it in 2 quarters since.
  • 5 funds tracked by Wall St. Rank held Shuttle Pharmaceuticals as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.